The effect of deprenyl (selegiline) on the natural history of Parkinson's disease
about
Monoamine oxidase B inhibitors for early Parkinson's diseaseMonoamine oxidase type B inhibitors in early Parkinson's disease: meta-analysis of 17 randomised trials involving 3525 patientsBrown-Séquard's spinal epilepsy.A review of clinical trial designs used to detect a disease-modifying effect of drug therapy in Alzheimer's disease and Parkinson's diseaseInhibitors of MAO-A and MAO-B in Psychiatry and NeurologyOttawa's "Operation Meningo": "when the data are insufficient, you go with judgement"Structure of the human gene for monoamine oxidase type A.The IMAO-B MDL 72.974 A in Parkinson's disease.Controversies in neurology: why monoamine oxidase B inhibitors could be a good choice for the initial treatment of Parkinson's disease.Idiopathic Parkinson's disease: epidemiology, diagnosis and management.Psychology and women subject of Toronto conferenceDoctor at DieppeGrowing number of elderly patients will mean more ethical issues for MDs, conference toldNeuropharmacological actions of cigarette smoke: brain monoamine oxidase B (MAO B) inhibition.Pharmacological interventions in aging and age-associated disorders: potentials of propargylamines for human use.Vancouver psychiatrist's experiences lead to work with torture victims.The ethics of gene researchToronto hospital a real-life experiment in dealing with health care's new fiscal realities.Increased serum lithium levels due to ketorolac therapy.The effects of administration of monoamine oxidase-B inhibitors on rat striatal neurone responses to dopamine.Antioxidants as treatment for neurodegenerative disorders.Monoamine reuptake inhibitors in Parkinson's disease.Parkinsonism treatment: Part III--Update.Protection of the aged substantia nigra of the rat against oxidative damage by (-)-deprenyl.(-)Deprenyl-medication: a strategy to modulate the age-related decline of the striatal dopaminergic system.Antioxidative therapeutic strategies for Parkinson's disease.A Strategy to Employ Clitoria ternatea as a Prospective Brain Drug Confronting Monoamine Oxidase (MAO) Against Neurodegenerative Diseases and DepressionEarly onset Parkinson's disease. Part 2: Physician's viewpointForeign doctors. Wasted resources?Caring for adult survivors of child sexual abuse. Issues for family physicians.Neurology.Parkinson and his disease revisitedCurrent Pharmaceutical Treatments and Alternative Therapies of Parkinson's Disease.Protection against Parkinson's disease progression: clinical experience.Pathogenesis-targeted, disease-modifying therapies in Parkinson disease.Mitochondria and energetic depression in cell pathophysiologyDifferential vulnerability of primate caudate-putamen and striosome-matrix dopamine systems to the neurotoxic effects of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine.Pharmacological approaches to disease-modifying therapies in Parkinson's disease.Comparison for Efficacy and Tolerability among Ten Drugs for Treatment of Parkinson's Disease: A Network Meta-Analysis.Pharmacodynamic issues relevant to geriatric psychopharmacology.
P2860
Q24246514-D28429BC-D966-4DD5-AA5C-F6C2A39298AAQ24561822-87934FEC-A3F6-41BA-B42A-3F8E452ADD3DQ24800649-FA6522B6-6EC4-49E6-9498-E9EBF0ECC09AQ27311651-EB7D5718-848D-418B-B7E0-EA2C0106DB4DQ28069609-3F15E640-0BA4-42BA-AB7A-5FB37D8247A3Q30944785-DC651A68-F79E-4CC4-9F08-69AD1EACB4B0Q33376228-D46ACB5C-4A08-4ECA-A626-E1AFB891B2C2Q33592096-3E84DD06-8598-48FA-8885-C6336C6992E8Q34027880-88FDFB11-923F-4464-9E77-1E881F126C09Q34053847-E8AF9862-1A43-4EC9-A275-C7EABE933ACDQ34274775-E8B2F24F-F3AB-454F-8E6C-967EF3B33768Q34275474-1BC6341B-8C02-4476-8BCE-A739E7798F41Q34275602-2E92E875-C16E-4AE2-AF7C-92DA6A35136AQ34464750-1BDA7E83-3101-426A-AD85-E051C01FAADDQ34614515-E2F8F54F-DEEE-4666-AE19-7A56EA4D3D2EQ34707861-B361257C-FDCD-452F-BCFA-755B9CDFC073Q34708204-C3E6F52A-4353-4A08-8778-04B9CCBC6FCAQ34708322-77471D7B-FC91-44CE-8406-6EF35A239D9BQ34708549-50F6F7D2-07EF-441B-B342-65444BB02DAAQ34793630-490C8357-EB61-4D7E-BD99-4D481FC35002Q34974866-C1428510-5CE8-4D61-B72F-35B52B8A509FQ35165280-294EACC9-1F60-4C3D-BA5B-D13B3414E06BQ35252285-F93ED833-5D43-4290-8EB4-00FF8DB6DBE9Q35873611-61A5C173-E9E3-46BD-9A6E-BBE941C6A3A4Q36340002-26FE180F-944B-4C69-A09D-005B2095D522Q36349448-AAD57B1B-8F8A-4C0B-811F-2E3254065744Q36378454-91133AFC-738D-4874-901F-831E360A3C3CQ36653147-98158885-3268-423E-AFF3-9DE5A020631BQ36653245-01B7DE7D-BA23-4004-87F1-6E06D1AF66C2Q36653414-491A55FB-909B-46BB-93DC-DEBF3D7FCB0CQ36681764-9DA2B55E-5206-42A7-9EDA-787B65187A40Q36681983-646C59BE-DD0B-49FA-9D4A-8E4977AD1388Q36925905-4C233186-AD7C-4EE6-8B4A-4E1BD93F0794Q37131239-4B550841-A5D0-424B-BDF5-6F2F689C9F00Q37506492-1FBF9A91-AC1E-4F0F-9909-ADFE01D79B56Q37535535-98EE6499-9C98-4CB3-9853-B4A8EDFD4460Q37599177-082D850F-7BCF-49F0-9BE0-DB78D6EB09BBQ37610212-DD05ED55-3247-4127-81AD-DE17D4779031Q37736512-C68977BB-A263-4446-B5B8-FEF825A7001FQ37781948-9828D0F3-AB5A-4DC2-AFAF-367AD923DA20
P2860
The effect of deprenyl (selegiline) on the natural history of Parkinson's disease
description
1989 nî lūn-bûn
@nan
1989 թուականի Օգոստոսին հրատարակուած գիտական յօդուած
@hyw
1989 թվականի օգոստոսին հրատարակված գիտական հոդված
@hy
1989年の論文
@ja
1989年論文
@yue
1989年論文
@zh-hant
1989年論文
@zh-hk
1989年論文
@zh-mo
1989年論文
@zh-tw
1989年论文
@wuu
name
The effect of deprenyl (selegiline) on the natural history of Parkinson's disease
@ast
The effect of deprenyl (selegiline) on the natural history of Parkinson's disease
@en
The effect of deprenyl (selegiline) on the natural history of Parkinson's disease
@nl
type
label
The effect of deprenyl (selegiline) on the natural history of Parkinson's disease
@ast
The effect of deprenyl (selegiline) on the natural history of Parkinson's disease
@en
The effect of deprenyl (selegiline) on the natural history of Parkinson's disease
@nl
prefLabel
The effect of deprenyl (selegiline) on the natural history of Parkinson's disease
@ast
The effect of deprenyl (selegiline) on the natural history of Parkinson's disease
@en
The effect of deprenyl (selegiline) on the natural history of Parkinson's disease
@nl
P3181
P356
P1433
P1476
The effect of deprenyl (selegiline) on the natural history of Parkinson's disease
@en
P2093
J W Langston
J W Tetrud
P304
P3181
P356
10.1126/SCIENCE.2502843
P407
P577
1989-08-04T00:00:00Z